Differences in socio-demographic and risk factor profile, clinical presentation, and outcomes between patients with and without RHD heart failure in Sub-Saharan Africa: results from the THESUS-HF registry by Nkoke, Clovis et al.
eCommons@AKU 
Internal Medicine, East Africa Medical College, East Africa 
8-2021 
Differences in socio-demographic and risk factor profile, clinical 
presentation, and outcomes between patients with and without 







See next page for additional authors 
Follow this and additional works at: https://ecommons.aku.edu/eastafrica_fhs_mc_intern_med 
 Part of the Cardiology Commons 
Authors 
Clovis Nkoke, Albertino Damasceno, Christopher Edwards, Beth Davison, Gad Cotter, Mahmoud Sani, 
Lauren Gaeta, Okechukwu S. Ogah, Charles Mondo, and Gerald Yonga 
© Cardiovascular Diagnosis and Therapy. All rights reserved. Cardiovasc Diagn Ther 2021;11(4):980-990 | https://dx.doi.org/10.21037/cdt-21-112
Original Article
Differences in socio-demographic and risk factor profile, clinical 
presentation, and outcomes between patients with and without 
RHD heart failure in Sub-Saharan Africa: results from the  
THESUS-HF registry
Clovis Nkoke1,2, Albertino Damasceno3, Christopher Edwards4, Beth Davison4,5, Gad Cotter4,5,  
Mahmoud Sani6, Lauren Gaeta4, Okechukwu S. Ogah7, Charles Mondo8, Dike Ojji9, Ahmed Suliman10, 
Gerald Yonga11, Serigne Abdou Ba12, Anastase Dzudie2,13, Karen Sliwa14
1Department of Internal Medicine, Buea Regional Hospital, Buea, Cameroon; 2Clinical Research Education, Networking and Consultancy, Douala, 
Cameroon; 3Eduardo Mondlane University, Maputo, Mozambique; 4Momentum Research Inc., Durham, North Carolina, USA; 5U 942 Inserm-
MASCOT, Paris, France; 6Department of Medicine, Bayero University Kano/Aminu Kano Teaching Hospital, Kano, Nigeria; 7Cardiology Unit, 
Department of Medicine, University of Ibadan/University College Hospital, Ibadan, Oyo State; 8Kiruddu National Referral Hospital, Kampala, 
Uganda; 9Cardiology Unit, Department of Medicine, University of Abuja Teaching Hospital, Abuja, Nigeria; 10Faculty of Medicine, University 
of Khartoum, Khartoum, Sudan; 11Department of Medicine, Aga Khan University, Nairobi, Kenya; 12Service de cardiologie, Faculte de medecine 
de Dakar, Dakar, Senegal; 13Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaoundé, Cameroon; 14Hatter Institute for 
Cardiovascular Research in Africa, Cape Town, South Africa
Contributions: (I) Conception and design: C Nkoke, A Damasceno, B Davison, G Cotter; (II) Administrative support: A Damasceno, B Davison, G 
Cotter, M Sani, L Gaeta, OS Ogah, G Yonga, A Dzudie, K Silwa; (III) Provision of study materials or patients: A Damasceno, M Sani, OS Ogah, C 
Mondo, D Ojji, A Suliman, G Yonga, SA Ba, A Dzudie, K Silwa; (IV) Collection and assembly of data: A Damasceno, C Edwards, B Davison, M Sani, 
OS Ogah, C Mondo, D Ojji, A Suliman, G Yonga, SA Ba, A Dzudie, K Silwa; (V) Data analysis and interpretation: C Nkoke, C Edwards, B Davison; 
(VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.
Correspondence to: Clovis Nkoke. Buea Regional Hospital, Buea, Cameroon. Email: cnkoke@yahoo.com.
Background: Rheumatic heart disease (RHD) was found in the THESUS-HF registry to be the third most 
common cause of acute heart failure (AHF) in Sub-Saharan Africa. 
Methods: One thousand six patients with AHF from 9 Sub-Saharan African countries were recruited in 
THESUS-HF, of which 143 (14.3%) had RHD-AHF. Clinical characteristics and outcomes in patients with 
RHD-AHF and non-RHD-AHF were compared. Kaplan-Meier plots for time to all-cause death and/or 
HF readmission according to the presence of RHD-AHF and non-RHD-AHF were performed and survival 
distributions compared using the log-rank test. Cox regression was used to determine the hazard ratio of 
death to day 180 and death or readmission to day 60 after adjusting for confounders. 
Results: Patients with RHD-AHF were younger, more often females, had higher rates of atrial fibrillation, 
had less hypertension, hyperlipidemia and diabetes, had lower BP, and higher pulse rate and better kidney 
function and echocardiographic higher ejection fraction larger left atria and more diastolic dysfunction. 
Patients with RHD-AHF had a numerically longer mean stay in the hospital (10.5 vs. 8.8 days) and 
significantly higher initial hospitalization mortality (9.1% vs. 3.4%). 
Conclusions: In conclusion, patients with HF related to RHD were younger, have higher rate of atrial 
fibrillation and have a worse short-term outcome compared to HF related to other etiologies in Sub-Saharan 
Africa.
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Introduction
Heart failure (HF) is a major cause of morbidity and 
mortality in developed and developing countries. Rheumatic 
heart disease (RHD) is the third leading cause of HF in 
Africa after hypertension and dilated cardiomyopathies as 
reported in a recent systematic review and meta-analysis (1). 
It was also the third most common HF etiology in the 
multinational sub-Saharan Africa Survey of Heart Failure 
(THESUS-HF) study (2). RHD diagnosis in Sub-Saharan 
Africa (SSA) is usually made at an advanced stage of the 
disease, when severe valve lesions become symptomatic, 
and there is need for invasive intervention (3). Severe RHD 
is lethal in the absence of invasive treatment. However, 
interventions such as percutaneous mitral dilatation, closed 
heart mitral commissurotomy and open-heart surgery can 
be performed at only a few centers in Africa and are not 
usually affordable (4). Given the high prevalence of RHF 
and the high incidence of RHD-AHF in Africa, the current 
analysis was performed to compare the socio-demographic, 
clinical characteristics and outcome between patients 
admitted with acute heart failure (AHF) due to RHD 
and non-RHD (RHD-AHF and non-RHD-AHF) and 
followed during 6 months using data from the multinational 
THESUS-HF study. We present the protocol in accordance 
with the STROBE reporting checklist (available at https://
dx.doi.org/10.21037/cdt-21-112).
Methods
THESUS-HF was a prospective, multicenter, observational 
study of patients admitted between July 2007 and June 
2010 for AHF in 12 hospitals from nine countries in 
southern, eastern, central, and western sub-Saharan Africa, 
mostly in Nigeria, Uganda, and South Africa. Eligibility 
criteria included dyspnoea as the main complaint leading 
to admission and symptoms and signs of congestive 
heart failure including rales, oedema, and raised jugular 
venous pulse. Echocardiographic findings supported 
the diagnosis which a cardiologist confirmed. Patients’ 
written informed consent was required for entry into the 
study. Each participating institution’s ethics committee 
approved the study, which conformed to the principles of 
the Declaration of Helsinki.. Investigators recorded data 
onto standardized case report forms, and data collected 
included medical history, medication use, laboratory 
values, and physical examination with heart failure signs 
and symptoms. Echocardiographic assessments were made 
locally and electrocardiograms were read centrally. Tests 
for human immunodeficiency virus were done if clinically 
indicated. The occurrence of readmissions and/or death 
over 6 months was assessed either at clinic visits or through 
telephone contacts. 
Statistical analysis
Nine patients where the diagnosis of RHD was not available 
were excluded from all analyses. Results are presented 
as counts and percentages for categorical variables and 
means, standard deviation (SD), median and 25th–75th 
percentiles for continuous variables. Comparison between 
participants with RHD-HF and those with non RHD-
HF for demographics, baseline clinical characteristics, 
medical history, echocardiographic parameters, and 
baseline medication use were tested using chi square tests 
for qualitative variables, Wilcoxon rank-sum for ordinal 
variables, and t-test for quantitative variables. 
The associations between RHD-AHF or non-RHD-
AHF clinical outcomes were examined. A t-test was used 
for comparing length of initial hospital stay between 
groups. In-hospital mortality was compared between groups 
using a logistic regression model with the odds ratio, 95% 
confidence interval, and Wald chi-square P value presented. 
For time-to-event outcomes, Kaplan-Meier estimates 
are presented with the log rank test used for comparison 
between groups; hazard ratios and 95% confidence intervals 
from Cox regression models are also given. Hazard ratios 
adjusting for predictors found to be associated with 
readmission or death to day 60 and all-cause death to day 
180 are also presented (5). These predictors include history 
of hyperlipidemia, malignancy, and cor pulmonale and; 
baseline rales, ejection fraction, BUN, and systolic BP for 
death or readmission to Day 60 and history of malignancy, 
cor pulmonale, and HIV; gender, smoking status, and 
baseline values for systolic BP, creatinine, hemoglobin, 
heart rate, orthopnea, rales, and edema for death to day 
180. Multiple imputation methods were used to account 
for missing predictors in the adjusted analyses. Rubin’s 
algorithm (SAS PROC MIANALYZE) was used to average 
parameter estimates across seven imputation datasets. Plots 
of Kaplan-Meier curves for time to all-cause death and/or 
HF readmission according to the presence of RHD-HF and 
non-RHD-HF are shown. Data were analyzed using SAS 
software version 9.4 (SAS Institute, Cary, NC, USA). A P 
value <0.05 was considered statistically significant.
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Results
Socio-demographic and risk factor profile
One thousand six (1,006) patients with AHF from nine 
sub-Saharan African countries were recruited in THESUS-
HF, of which 997 were included in this analysis. There 
were 143 patients (14.3%) with RHD-AHF (Figure 1). 
Comparison of socio-demographic and risk factor profile is 
shown in Table 1. Most of the patients were black Africans 
(99%). The mean age (SD) was 52.3 (18.3) years, and 489 
(49.1%) were males. Patients with heart failure associated 
with RHD were younger (42.5 vs. 54.0 years), were more 
likely to be females, and were more likely to have atrial 
fibrillation (42.9% vs. 14.5%). Patients with non-RHD-
AHF had higher rates of hypertension, diabetes mellitus, 
and hypercholesterolemia. In laboratory examinations they 
had worst kidney function and higher glucose, but less 
leukocytosis. 
Comparison of clinical and echocardiographic 
characteristics
Comparison of clinical presentation is shown in Table 2. 
Patients with heart failure associated with RHD had 
significantly lower systolic (118 vs. 132.4 mmHg) and 
diastolic (76.2 vs. 85.7 mmHg) blood pressures, lower 
severity of peripheral oedema and a higher mean ejection 
fraction (48.1% vs. 38.1%). The mean eGFR and WBC 
were significantly higher in patients with RHD-HF. The 
echocardiographic evaluation is shown in Table 3. Patients 
with RHD-HF had significantly higher left atrial size (54.6 
vs. 46 mm), lower LV end systolic diameter and higher 
ejection fraction and higher mitral inflow variables such as 
e wave deceleration time. The mean left ventricular end-
systolic diameter was lower in RHD-HF patients.
Comparison of oral medications at baseline
The oral medication use is shown in Table 4. Patients with 
RHD-HF were significantly more likely to be prescribed 
beta-blockers (28.9% vs. 14.4%), however, the prescription 
of beta blockers in patients with RHD-HF was not 
influenced by the presence of atrial fibrillation. At admission 
28.3% of patients with RHD-HF who were in atrial 
fibrillation received beta blockers versus 29.1% of those 
who were not in atrial fibrillation. Patients with RHD-HF 
were less likely to be prescribed the RAAS blockers (54.3% 
vs. 77%). The pattern of prescription of other medications 
was similar in both groups. 
Comparison of clinical outcomes
The clinical outcomes (length of hospital stay, readmission 
and death) are shown in Table 5. Length of initial stay was 
available for 863 (86.6%) of the 997 patients; length of 
stay was considered missing for 42 patients who died in-
hospital and 92 patients were missing the discharge date. 
Patients with RHD-HF had a numerically, though non-
significantly, longer length of initial stay in the hospital 
(10.5 vs. 8.8 days) but had significantly higher initial 
hospitalization mortality (9.1% vs. 3.4%). Readmission 
at 60 days was comparable between groups (Figure 2A). 
Patients with RHD-HF had a slightly higher estimated 
rate of all-cause death or readmission through 60 days 
(Figure 2B), although the difference was not statistically 
significant. At 180 days, patients with RHD-HF had a 
similar risk of death (Figure 2C).
Discussion
The etiology, medical management, and short-term 
clinical outcomes of 1,006 Africans with AHF from nine 
SSA countries were described in the sub-Saharan Africa 
Survey of Heart Failure (THESUS-HF) (2). In this study, 
RHD was the third most common cause of heart failure 
in SSA. RHD has virtually disappeared in high income 
countries but prevails as a major cause of cardiovascular 
death and disability in children and young adults in low- 
Patients with acute heart failure 
(AHF) (n=1,006)
lncluded in Analysis (n=997)
RHD-AHF (n=143) 
(14.3%)
Non RHD-AHF (n=854) 
(85.7%)
Excluded (n=9)
• Diagnosis of RHD 
not available (n=9)
Figure 1 Analysis flow chart.
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Table 1 Comparison of sociodemographic and risk factor profile
Variables Overall (N=997) RHD-HF group (N=143) Non-RHD-HF group (N=854) P value#
Country, n (%)
Cameroon 90 (9.0) 10 (7.0) 80 (9.4) <0.0001
Ethiopia 10 (1.0) 1 (0.7) 9 (1.1)
Kenya 32 (3.2) 1 (0.7) 31 (3.6)
Mozambique 76 (7.6) 8 (5.6) 68 (8.0)
Nigeria 422 (42.3) 29 (20.3) 393 (46.0)
Senegal 15 (1.5) 3 (2.1) 12 (1.4)
South Africa 129 (12.9) 40 (28.0) 89 (10.4)
Sudan 71 (7.1) 15 (10.5) 56 (6.6)
Uganda 152 (15.2) 36 (25.2) 116 (13.6)
Age, years
Mean (SD) 52.3 (18.28) 42.5 (17.10) 54.0 (17.96) <0.0001
Median (Q1, Q3) 55.0 (39.0, 67.0) 42.5 (26.0, 55.0) 56.0 (41.0, 69.0)
Male sex, n (%) 489 (49.1) 54 (37.8) 435 (51.0) 0.0034
Black African, n (%) 980 (99.0) 141 (98.6) 839 (99.1) 0.6155
Atrial fibrillation, n (%) 183 (18.5) 60 (42.9) 123 (14.5) <0.0001
No. of AHF admission in prior 12 months
Mean (SD) 0.4 (0.78) 0.5 (0.79) 0.4 (0.77) 0.1363
Median (Q1, Q3) 0.0 (0.0, 0.0) 0.0 (0.0, 1.0) 0.0 (0.0, 0.0)
Past history, n (%)
Hyperlipidemia 90 (9.2) 6 (4.3) 84 (10.1) 0.0269
Smoking 97 (9.8) 11 (7.7) 86 (10.1) 0.3661
Hypertension 551 (55.5) 40 (28.0) 511 (60.1) <0.0001
Diabetes 113 (11.4) 3 (2.1) 110 (12.9) 0.0002
Malignancy 13 (1.3) 1 (0.7) 12 (1.4) 0.4888
Cor pulmonale 72 (7.3) 9 (6.3) 63 (7.5) 0.6161
Body mass index
Mean (SD) 24.9 (5.82) 24.3 (6.75) 24.9 (5.65) 0.2341
Median (Q1, Q3) 23.9 (20.9, 28.0) 23.3 (20.1, 27.1) 24.1 (20.9, 28.1)
#P value from t-test for continuous variables or from χ2-test for categorical variables. RHD, rheumatic heart disease; SD, standard 
deviation; Q1, first quartile; Q3, third quartile.
and middle-income countries, including SSA (6-8). The 
aim of this study was to compare the socio-demographic 
and risk factor profile, clinical characteristics, and outcomes 
between patients with RHD heart failure and Non-RHD 
heart failure in SSA using data from the THESUS heart 
failure registry (2). These analyses showed that patients 
with HF associated with RHD were: younger, more were 
females, were more likely to be in atrial fibrillation, had less 
hypertension, hyperlipidemia and diabetes, had lower BP, 
and higher pulse rate and better kidney function but more 
984 Nkoke et al. Rheumatic heart disease in Sub-Saharan Africa
© Cardiovascular Diagnosis and Therapy. All rights reserved. Cardiovasc Diagn Ther 2021;11(4):980-990 | https://dx.doi.org/10.21037/cdt-21-112
Table 2 Comparison of clinical presentation
Variables Overall (N=997) RHD-HF group (N=143) Non-RHD-HF group (N=854) P value#
NYHA Class, n (%)
I 118 (17.9) 17 (15.2) 101 (18.4) 0.5741
II 302 (45.7) 60 (53.6) 242 (44.1)
III 213 (32.2) 31 (27.7) 182 (33.2)
IV 28 (4.2) 4 (3.6) 24 (4.4)
Systolic BP, mmHg
Mean (SD) 130.4 (33.54) 118.0 (24.70) 132.4 (34.38) <0.0001
Median (Q1, Q3) 127.0 (106.0, 150.0) 111.0 (100.0, 130.0) 130.0 (110.0, 151.0)
Diastolic BP, mmHg
Mean (SD) 84.4 (20.86) 76.2 (19.46) 85.7 (20.79) <0.0001
Median (Q1, Q3) 80.0 (70.0, 100.0) 72.0 (62.0, 90.0) 83.5 (70.0, 100.0)
Heart rate, bpm
Mean (SD) 103.7 (21.58) 105.5 (26.39) 103.4 (20.66) 0.2709
Median (Q1, Q3) 104.0 (90.0, 116.0) 102.0 (89.0, 120.0) 104.0 (90.0, 116.0)
Peripheral edema, n (%)
0 154 (15.7) 22 (15.6) 132 (15.7) 0.0291
1 166 (16.9) 30 (21.3) 136 (16.2)
2 355 (36.2) 60 (42.6) 295 (35.1)
3+ 306 (31.2) 29 (20.6) 277 (33.0)
Rales, n (%)
No rales 117 (13.4) 19 (17.9) 98 (12.8) 0.7000
Rales <1/3 191 (21.9) 24 (22.6) 167 (21.8)
Rales 1/3–2/3 410 (47.1) 39 (36.8) 371 (48.5)
Rales >2/3 153 (17.6) 24 (22.6) 129 (16.9)
Ejection fraction, %
Mean (SD) 39.6 (16.35) 48.1 (14.88) 38.1 (16.15) <0.0001
Median (Q1, Q3) 38.0 (27.0, 50.0) 47.3 (40.0, 58.0) 35.4 (25.2, 48.0)
Creatinine, mg/dL
Mean (SD) 1.4 (1.04) 1.2 (0.70) 1.4 (1.08) 0.0454
Median (Q1, Q3) 1.1 (0.9, 1.5) 1.1 (0.9, 1.4) 1.1 (0.9, 1.5)
BUN, mg/dL
Mean (SD) 35.5 (32.95) 30.9 (24.89) 36.3 (34.09) 0.0772
Median (Q1, Q3) 26.8 (16.8, 41.7) 22.1 (14.3, 40.0) 27.8 (17.2, 42.0)
Table 2 (continued)
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Table 2 (continued)
Variables Overall (N=997) RHD-HF group (N=143) Non-RHD-HF group (N=854) P value#
eGFR, mL/min/1.73 m2
Mean (SD) 83.9 (47.53) 92.2 (59.73) 82.4 (44.93) 0.0239
Median (Q1, Q3) 77.1 (55.0, 103.8) 79.9 (62.1, 107.0) 76.8 (53.3, 103.5)
Cholesterol, mg/dL
Mean (SD) 157.6 (54.25) 148.4 (41.57) 159.2 (56.07) 0.0701
Median (Q1, Q3) 152.1 (124.0, 187.0) 152.1 (114.7, 171.6) 153.3 (124.8, 187.2)
Triglycerides, mg/dL
Mean (SD) 106.3 (53.94) 98.2 (40.31) 107.7 (55.92) 0.1127
Median (Q1, Q3) 97.9 (71.2, 124.6) 90.5 (67.3, 115.7) 97.9 (71.2, 127.3)
Glucose, mg/dL
Mean (SD) 109.8 (49.85) 99.3 (44.16) 111.5 (50.55) 0.0114
Median (Q1, Q3) 93.7 (84.0, 117.0) 91.8 (82.8, 101.7) 95.0 (84.6, 120.0)
Hemoglobin, g/dL
Mean (SD) 12.2 (2.42) 12.0 (2.07) 12.2 (2.47) 0.4753
Median (Q1, Q3) 12.3 (10.7, 13.7) 12.0 (10.5, 13.3) 12.3 (10.7, 13.8)
Lymphocytes, %
Mean (SD) 30.3 (13.37) 28.4 (13.16) 30.6 (13.39) 0.0986
Median (Q1, Q3) 30.0 (20.0, 39.6) 29.0 (19.0, 36.5) 30.0 (20.4, 40.0)
Sodium, mmol/L
Mean (SD) 135.1 (6.61) 135.1 (6.55) 135.1 (6.63) 0.9192
Median (Q1, Q3) 135.3 (131.0, 139.0) 136.0 (131.5, 139.0) 135.0 (131.0, 139.2)
WBC, No./µL
Mean (SD) 7,689.0 (4,101.53) 8,826.5 (5,542.82) 7,495.0 (3,772.01) 0.0004
Median (Q1, Q3) 6,800.0 (5,200.0, 8,960.0) 7,200.0 (5,700.0, 9,900.0) 6,700.0 (5,090.0, 8,800.0)
#P value from  t-test  for continuous variables, Wilcoxon rank-sum test for ordinal variables, and χ2-test for categorical variables. RHD, 
rheumatic heart disease; SD, standard deviation; Q1, first quartile; Q3, third quartile; NYHA, New York Heart Association; BUN, blood urea 
nitrogen; eGFR, estimated glomerular filtration rate; WBC, white blood cell.
leukocytosis. By echocardiography patients with RHD-
AHD had higher ejection fraction but larger left atria and 
more diastolic dysfunction. The study also showed that 
RHD-HF patients were significantly more often prescribed 
beta blockers, had a significantly worse short-term outcome, 
especially higher mortality on initial hospitalization. 
However, the longer-term (60 and 180 days) outcomes did 
not differ significantly in patients with RHD-HF. Some 
of the differences observed between patients with RHD-
AHF and non-RHD AHF may be due to the fact that some 
specific subgroups of non-RHD AHF are more likely to 
have specific characteristics, such as higher BP in patients 
with hypertension related AHF. These differences cannot 
be explored here in detail due to the limited number of 
patients presenting with different AHF etiologies. 
To our knowledge this is the first study comparing 
patients with AHF associated with RHD to patients with 
other etiologies of AHF not related to RHD in SSA. 
Previous reports from SSA have shown that heart failure 
affects men and women in the most productive years of their 
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Table 3 Comparison of echocardiographic evaluations
Variables Overall (N=997) RHD-HF group (N=143) Non-RHD-HF group (N=854) P value#
Heart rate, bmp
Mean (SD) 94.8 (17.88) 98.5 (22.14) 94.1 (16.89) 0.0135
Median (Q1, Q3) 94.0 (84.0, 104.0) 98.0 (87.0, 110.0) 94.0 (84.0, 104.0)
Dimensions and LV function
LV systole size, mm
Mean (SD) 46.1 (13.16) 41.8 (12.18) 46.8 (13.19) <0.0001
Median (Q1, Q3) 47.0 (37.0, 55.0) 42.0 (32.0, 48.0) 48.0 (37.9, 56.0)
LV diastole size, mm
Mean (SD) 57.7 (11.59) 57.2 (12.20) 57.8 (11.49) 0.5757
Median (Q1, Q3) 58.0 (50.0, 65.0) 58.0 (49.0, 64.0) 58.4 (50.1, 65.0)
IV septum (diastole), mm
Mean (SD) 11.2 (3.25) 11.3 (3.12) 11.2 (3.27) 0.7483
Median (Q1, Q3) 11.0 (9.0, 13.0) 11.0 (9.0, 13.0) 11.0 (9.0, 13.0)
Posterior wall (diastole), mm
Mean (SD) 10.7 (2.88) 10.9 (2.63) 10.7 (2.92) 0.5293
Median (Q1, Q3) 10.1 (9.0, 12.8) 10.6 (9.0, 12.0) 10.0 (9.0, 13.0)
Diastolic function
Left atrial planimetry size, mm
Mean (SD) 47.1 (9.07) 54.6 (10.97) 46.0 (8.15) <0.0001
Median (Q1, Q3) 47.0 (41.0, 52.4) 53.0 (47.0, 61.0) 46.0 (41.0, 51.0)
Left atrial planimetry size, mm2
Mean (SD) 2,768.0 (928.15) 3,624.1 (1,147.45) 2,637.6 (816.06) <0.0001
Median (Q1, Q3) 2,620.0 (2,200.0, 3,240.0) 3,410.0 (2,930.0, 4,220.0) 2,560.0 (2,103.0, 3,100.0)
Mitral E wave, cm/s
Mean (SD) 54.3 (50.08) 87.0 (83.02) 49.8 (41.90) <0.0001
Median (Q1, Q3) 47.6 (9.6, 88.0) 70.3 (12.0, 148.0) 47.0 (9.3, 82.0)
E wave deceleration time, ms
Mean (SD) 150.0 (92.93) 216.4 (199.44) 141.2 (62.43) <0.0001
Median (Q1, Q3) 130.0 (100.0, 171.0) 162.5 (110.5, 224.5) 130.0 (100.0, 167.0)
Mitral A wave, cm/s
Mean (SD) 36.5 (34.62) 55.7 (57.75) 34.7 (30.99) <0.0001
Median (Q1, Q3) 30.0 (6.2, 55.0) 36.0 (6.2, 87.0) 29.5 (6.2, 54.0)
Mitral A wave duration time, ms
Mean (SD) 126.0 (44.99) 138.9 (78.77) 124.9 (40.51) 0.0472
Median (Q1, Q3) 123.0 (100.0, 150.0) 121.0 (100.0, 155.0) 123.0 (100.0, 150.0)
#P value from t-test. RHD, rheumatic heart disease; SD, standard deviation; Q1, first quartile; Q3, third quartile; LV, left ventricular; IV, 
interventricular.
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Table 4 Comparison of prescribed oral medication use at admission
Variable, n (%) Overall (N=997) RHD-HF group (N=143) Non-RHD-HF group (N=854) P value#
ACEi/ARBs 726 (73.8) 76 (54.3) 650 (77.0) <0.0001
Loop diuretics 155 (16.0) 27 (19.3) 128 (15.5) 0.2561
Beta blockers 161 (16.5) 41 (28.9) 120 (14.4) <0.0001
Digoxin 433 (44.3) 63 (44.1) 370 (44.4) 0.9453
Hydralazine 12 (1.2) 1 (0.7) 11 (1.3) 0.5380
Nitrates 50 (5.1) 8 (5.6) 42 (5.0) 0.7555
Aldosterone inhibitors 643 (65.7) 86 (60.6) 557 (66.5) 0.1649
Statins 100 (10.3) 14 (9.9) 86 (10.4) 0.8724
Aspirin 351 (35.8) 45 (31.7) 306 (36.5) 0.2674
Anticoagulants 337 (34.3) 53 (37.3) 284 (33.8) 0.4146
#P value from χ2-test. RHD, rheumatic heart disease; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker.











Length of initial hospital stay, days
Mean (SD) 10.5 (15.08) 8.8 (8.79) 0.0684
Median (Q1, Q3) 7.0 (5.0, 9.0) 7.0 (5.0, 10.0)
Initial hospitalization mortality, n (%) 13 (9.1) 29 (3.4) 0.0017 2.84 (1.44, 5.61) –
Readmission to day 60, n (KM %) 9 (8.2) 65 (9.3) 0.6604 0.86 (0.43, 1.72) –
Death to day 60, n (KM %) 18 (13.5) 77 (10.2) 0.1591 1.44 (0.86, 2.41) –
Death or readmission to day 60, n (KM %) 25 (19.2) 113 (15.1) 0.1605 1.36 (0.88, 2.10) 1.40 (0.88, 2.25)
Death to day 180, n (KM %) 25 (19.7) 126 (17.6) 0.3536 1.22 (0.80, 1.88) 1.10 (0.71, 1.70)
#P value from ANOVA (F-test) for length of initial stay, log-rank test for time-to event outcomes, and Wald-χ2-from a logistic regression 
model for in-hospital mortality. 1Odds ratio (95% CI) provided for in-hospital mortality outcome. 2Multiple imputations used adjusting for 
the following predictors. Death to day 180: gender, history of malignancy, history of cor pulmonale, history of HIV, smoking status, and 
baseline values for systolic BP, creatinine, hemoglobin, heart rate, orthopnea, rales, and edema. Death or readmission to day 60: history 
of hyperlipidemia, history of malignancy, history of cor pulmonale, and baseline values for rales, ejection fraction, BUN, and systolic 
BP. RHD, rheumatic heart disease; SD, standard deviation; Q1, first quartile; Q3, third quartile; KM, Kaplan-Meier; OR, odds ratio; HR, 
hazard ratio. 
lives with a mean age of 52 years (2). The characteristics 
and outcomes of AHF related to RHD are not commonly 
reported and this series addresses a significant knowledge 
gap addressing RHD associated AHF. In this analysis, 
patients with RHD-AHF were significantly younger with 
a mean age of 42 years, compared to patients with other 
heart failure etiologies. The mean admission blood pressure 
was lower in patients with RHD-AHF probably because 
hypertension was the main etiology of non RHD-AHF, 
increasing this way the blood pressure in this group. 
The prevalence of atrial fibrillation among patients with 
RHD-AHF was 42% compared to 14.5% in non RHD-
AHF. Atrial fibrillation is one of the main complications of 
RHD and its prevalence increases with severity of valvular 
lesion. A study in Ethiopia reported a high prevalence of 
atrial fibrillation in patients with RHD (46.8%) which is 
comparable to that reported in this study (9). This was 
however higher than that reported in the REMEDY study 
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with a prevalence of atrial fibrillation of 21% (10). RHD 
is associated with a large atrium. An enlarged atrium is 
predictor of atrial fibrillation as shown by several studies 
(11,12), a finding that was also observed in the current 
analysis where patients had larger left atria. These findings 
suggest that atrial fibrillation is more common in patients 
with RHD admitted due to AHF then those with chronic, 
more compensated RHD. 
The prescription of beta blockers in patients with 
heart failure in SSA is low (1,13). In this report, patients 
with RHD-AHF were more likely to be prescribed beta 
blockers. This could be explained by a higher prevalence of 
atrial fibrillation with higher heart rates in these patients. 
Mitral stenosis, being an indisputable indication for beta 
blockers could also be a reason for this difference. Patients 
with RHD-AHF were also less likely to be prescribed 
angiotensin converting enzyme inhibitors which could be 
related to the higher left ventricular ejection fraction. 
Heart failure is a leading cause of morbidity and hospital 
readmission (14). In the current analysis, patients with 
RHD-AHF had higher initial hospitalization mortality, 
and a trend toward higher initial hospital length of stay. 
However, by 6 months follow up the outcomes of patients 
with AHF were similar regardless of whether the AHF was 
due to RHD or other causes. This information is addressing 
an important knowledge gap regarding the course and 
short-term outcomes of RHD related AHF. 
Although we don’t know the number of patients with 
RHD-AHF that underwent surgery, limited access to surgical 
treatment can explain in part the higher risk of early adverse 
outcome in patients with RHD-AHF in this analysis. RHD 
is usually diagnosed late in Africa with patients presenting 
late with advanced disease leading to high morbidity and 
mortality (15). The REMEDY study demonstrated that 
patients with RHD often present with moderate-to-severe 
multivalvular disease (63.9%), heart failure (33.4%), and 
pulmonary hypertension (28.8%); atrial fibrillation (21.8%), 
stroke (7.1%), and infective endocarditis (4%) are also 
seen (10). In this background of low- and middle-income 
countries, prohibitive costs and limited access to surgical and 
catheter-based interventions leave few options for treatment 
of such late presentations (16). These factors can explain the 
increased mortality and readmission in patients with heart 
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Figure 2 Kaplan-Meier survival plots for (A) all-cause readmission through day 60, (B) all-cause death or readmission through day 60, and (C) 
all-cause death through day 180.
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Conclusions
This series is the first to report on the characteristics and 
short-term outcomes of patients with RHD related AHF 
in recent years. Our data suggest that patients with AHF 
related to RHD are younger, have a higher prevalence of 
atrial fibrillation and have a worse outcome during the 
initial admission compared to heart failure related to other 
etiologies in SSA, however by 6 months their outcomes are 
similar to other patients with AHF not related to RHD. 
Limitations
The current analysis of the THESUS-HF registry is post-
hoc. As such it is limited by the nature of the post-Hoc 
analyses. Some of the comparisons described between 
RHD-AHF patients and non-RHD-AHF patients may 
be driven due to differences in specific subgroups of non-
RHD-AHF such as hypertensive, HIV or postpartum 
cardiomyopathy. More detailed analysis of such contrast 
could not be performed due to the size of the subgroups 
and hence small numbers of events in each group. Data on 
the number of patients who underwent surgery for RHD 
are not available in THESUS-HF. Data regarding the 
type of valvular lesions in patients with RHD-HF is also 
unavailable in this cohort. Despite these limitations, this 
paper serves to highlight an important facet of a neglected 
disease from the regions where it has the greatest impact in 
terms of mortality and morbidity. Thus, there is need for 
increased advocacy on RHD in SSA. 
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